RO: Core profit up 10% with strong pipeline progress and guidance reaffirmed for 2026
Core operating profit grew 10% year-over-year, outpacing 6% sales growth, with margin expansion and strong contributions from both Pharma and Diagnostics. Pipeline momentum remains high, with five FDA priority reviews and major launches in both divisions. Full-year guidance for mid-single-digit sal…